JP2016536369A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536369A5
JP2016536369A5 JP2016552455A JP2016552455A JP2016536369A5 JP 2016536369 A5 JP2016536369 A5 JP 2016536369A5 JP 2016552455 A JP2016552455 A JP 2016552455A JP 2016552455 A JP2016552455 A JP 2016552455A JP 2016536369 A5 JP2016536369 A5 JP 2016536369A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
composition according
binding protein
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536369A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/063951 external-priority patent/WO2015069668A1/en
Publication of JP2016536369A publication Critical patent/JP2016536369A/ja
Publication of JP2016536369A5 publication Critical patent/JP2016536369A5/ja
Pending legal-status Critical Current

Links

JP2016552455A 2013-11-05 2014-11-04 抗vegf darpinを用いた眼の容態の治療方法 Pending JP2016536369A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361900246P 2013-11-05 2013-11-05
US61/900,246 2013-11-05
US201462016620P 2014-06-24 2014-06-24
US62/016,620 2014-06-24
PCT/US2014/063951 WO2015069668A1 (en) 2013-11-05 2014-11-04 Method of treating conditions of the eye with an anti-vegf darpin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020106978A Division JP2020169191A (ja) 2013-11-05 2020-06-22 抗vegf darpinを用いた眼の容態の治療方法

Publications (2)

Publication Number Publication Date
JP2016536369A JP2016536369A (ja) 2016-11-24
JP2016536369A5 true JP2016536369A5 (cg-RX-API-DMAC7.html) 2018-02-22

Family

ID=51947485

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016552455A Pending JP2016536369A (ja) 2013-11-05 2014-11-04 抗vegf darpinを用いた眼の容態の治療方法
JP2020106978A Pending JP2020169191A (ja) 2013-11-05 2020-06-22 抗vegf darpinを用いた眼の容態の治療方法
JP2022076645A Pending JP2022107628A (ja) 2013-11-05 2022-05-06 抗vegf darpinを用いた眼の容態の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020106978A Pending JP2020169191A (ja) 2013-11-05 2020-06-22 抗vegf darpinを用いた眼の容態の治療方法
JP2022076645A Pending JP2022107628A (ja) 2013-11-05 2022-05-06 抗vegf darpinを用いた眼の容態の治療方法

Country Status (14)

Country Link
US (4) US20150126458A1 (cg-RX-API-DMAC7.html)
EP (2) EP3628324A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016536369A (cg-RX-API-DMAC7.html)
KR (1) KR20160070164A (cg-RX-API-DMAC7.html)
CN (1) CN105960247A (cg-RX-API-DMAC7.html)
AU (2) AU2014346921A1 (cg-RX-API-DMAC7.html)
CA (1) CA2927012A1 (cg-RX-API-DMAC7.html)
DK (1) DK3065761T3 (cg-RX-API-DMAC7.html)
ES (1) ES2773317T3 (cg-RX-API-DMAC7.html)
HU (1) HUE047910T2 (cg-RX-API-DMAC7.html)
PL (1) PL3065761T3 (cg-RX-API-DMAC7.html)
PT (1) PT3065761T (cg-RX-API-DMAC7.html)
TW (1) TWI729970B (cg-RX-API-DMAC7.html)
WO (1) WO2015069668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
HUE046134T2 (hu) 2012-05-07 2020-02-28 Allergan Inc Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度vegf受容体融合タンパク質を含む製剤
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
CA3139164A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
IL301762A (en) * 2020-10-07 2023-05-01 Line 6 Biotechnology Inc Methods and materials for the treatment of eye diseases
EP4225129A4 (en) * 2020-10-08 2024-11-06 Notal Vision Ltd. OCT GUIDED THERAPY
CN114075290B (zh) * 2022-01-20 2022-04-19 南京鼓楼医院 Cd40靶向结合蛋白、其编码核酸以及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146890A0 (en) 1999-06-08 2002-08-14 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2007223888A1 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
HUE046134T2 (hu) * 2012-05-07 2020-02-28 Allergan Inc Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben

Similar Documents

Publication Publication Date Title
JP2016536369A5 (cg-RX-API-DMAC7.html)
AU2025271125A1 (en) Methods for treating or preventing ophthalmological conditions
JP6355032B2 (ja) 新規組換え二機能性融合タンパク質、それらの調製および使用
JP2020169191A5 (cg-RX-API-DMAC7.html)
US20220096596A1 (en) Method of treating amd in patients refractory to anti-vegf therapy
JP2016516016A5 (cg-RX-API-DMAC7.html)
JP2015502336A5 (cg-RX-API-DMAC7.html)
JP2016514132A5 (cg-RX-API-DMAC7.html)
JP2015522576A5 (cg-RX-API-DMAC7.html)
JP2017538395A5 (cg-RX-API-DMAC7.html)
JP2018535948A5 (cg-RX-API-DMAC7.html)
JP2022107628A (ja) 抗vegf darpinを用いた眼の容態の治療方法
JP2019531259A5 (cg-RX-API-DMAC7.html)
JP2015096065A5 (cg-RX-API-DMAC7.html)
RU2018119014A (ru) АНТИТЕЛА ПРОТИВ Нtr1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3250597A1 (en) Vegfa/ang2 compounds
AU2023336200A1 (en) Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
JP2009519025A5 (cg-RX-API-DMAC7.html)
JP2018509423A5 (cg-RX-API-DMAC7.html)
CN113195532B (zh) 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
JP2009538916A5 (cg-RX-API-DMAC7.html)
JP2012529423A5 (cg-RX-API-DMAC7.html)
Ghasemi Falavarjani et al. Hot topics in pharmacotherapy for neovascular age-related macular degeneration
US20240279324A1 (en) Multispecific antagonists
JPWO2022050176A5 (cg-RX-API-DMAC7.html)